Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan

Vaccine

Volumn 31, Issue 25, 2013, Pages 2762-2771

  Hoshi, Shu ling ^a   Kondo, Masahide ^a   Okubo, Ichiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cost effectiveness analysis; Pneumococcal conjugate vaccine; QALY; Vaccination programme

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; INCIDENCE; JAPAN; MENINGITIS; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; VACCINATION;

CHILD; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; JAPAN; MARKOV CHAINS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY-ADJUSTED LIFE YEARS; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84878374484     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.052     Document Type: Article

References (41)

1. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007, 82(12):93-104.
2. WHO position paper on pneumococcal vaccines-2012. Wkly Epidemiol Rec 2012, 87(14):129-144. http://www.who.int/wer.
3. Blank P.R., Szucs T.D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland. Vaccine 2012, 30(28):4267-4275.
4. Strutton D.R., Farkouh R.A., Earnshaw S.R., Hwang S., Theidel U., Kontodimas S., et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect 2012, 64(1):54-67.
5. Rubin J.L., McGarry L.J., Strutton D.R., Klugman K.P., Pelton S.I., Gilmore K.E., et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010, 28(48):7634-7643.
6. Tyo K.R., Rosen M.M., Zeng W., Yap M., Pwee K.H., Ang L.W., et al. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine 2011, 29(38):6686-6694.
7. Morozumi M., Chiba N., Okada T., Sakata H., Matsubara K., Iwata S., et al. Antibiotic susceptibility in relation to genotype of Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae responsible for community-acquired pneumonia in children. J Infect Chemother 2012, [Epub ahead of print].
8. Chiba N., Morizumi M., Sunaoshi K., Takahashi S., Sunakawa K., Ubukata K., et al. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect 2010, 138:61-68.
9. Trueman P., Drummond M., Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001, 19:609-621.
10. Hoshi S.L., Kondo M., Okubo I. Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan. Vaccine 2012, 30(22):3320-3328.
11. Skinner J.M., Indrawati L., Cannon J., Blue J., Winters M., Macnair J., et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011, 29(48):8870-8876.
12. Ministry of Health, Labour and Welfare Report on health center activities and health services for the year 2010 2011, Health and Welfare Statistics Association, Tokyo, [in Japanese].
13. ®: marketing brochure 2012, Pfizer Japan Inc., Tokyo, [in Japanese].
14. Preventive Vaccination Law, Supplementary Provisions, Extract, Pub. L. No. 116, Article 2; November 7, 2001.
15. Ministry of Internal Affairs and Communications Population estimates of Japan 2002, Statistics Bureau, Tokyo.
16. Sakata H., Shirai M., Kaijino M., Takase M., Okamoto T., Niura N., et al. Epidemiological study of bacterial meningitis in children in Kamikawa subprefecture in Hokkaido between 1988 and 2002. Acta Paediatr Jpn 2004, 108:401-405. [in Japanese].
17. Ministry of Health, Labour and Welfare Syoniyo haien kyukin wakutin, bihu wakutin no anzensei no hyouka kekka ni tuite March 24, 2011, Press release [in Japanese].
18. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010, 28(25):4192-4203.
19. Esposito S., Tansey S., Thompson A., Razmpour A., Liang J., Jones T.R., et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010, 17(6):1017-1026.
20. Kamiya H. Wakutin no yuyousei koujou no tame no ebidensu oyobi housaku ni kansuru kenkyu. Heisei 19 nendo-21 nendo sogo kenkyu hokokusho. Report of Health and Labour Sciences Research Grants 2010, Ministry of Health, Labour, and Welfare, Tokyo, [in Japanese].
21. Yamanaka N., Hotomi M., Sugita R. Cost-effectiveness of pneumococcal conjugate vaccine in Japan: estimation on acute pneumococcal otitis media in children. Jpn J Pediatr 2008, 61:2221-2232. [in Japanese].
22. Suzuki K., Kurono Y., Kobayashi T., Nishimura T., Baba S., Harabuchi Y., et al. The fourth nationwide survey of clinical isolates from patients with otolaryngological field infections. J Jpn Soc Infect Dis Otolaryngol 2008, 26:15-26. [in Japanese].
23. Takana J., Ishiwada N., Wada A., Chang B., Hishiki H., Kurosaki T., et al. Incidence of childhood pneumonia and serotype and sequence-type distribution in Streptococcus pneumonia isolates in Japan. Epidemiol Infect 2012, 140(6):1111-1121.
24. Iwata S., Ishiwada N., Sakata H., Sakano T., Sato Y., Nakano T., et al. Burden of illness of bacterial meningitis and bacteremia caused by Streptococcus pneumonia in children. Jpn J Pediatr 2008, 61:2206-2220. [in Japanese].
25. Social Statistics Division, Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare Heisei 20 nen kanja chosa 2008, Ministry of Health, Labour and Welfare, Tokyo, [in Japanese].
26. Ministry of Health, Labour and Welfare Vital statistics of Japan 2008, Health and Welfare Statistics Association, Tokyo, [in Japanese].
27. Lucero M.G., Dulalia V.E., Nillos L.T., Williams G., Parreño R.A.N., Nohynek H., et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009, (4). Art. No.: CD004977. 10.1002/14651858.CD004977.pub2.
28. Jansen A.G.S.C., Hak E., Veenhoven R.H., Damoiseaux R.A.M.J., Schilder A.G.M., Sanders E.A.M. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev 2009, (2). Art. No.: CD001480. 10.1002/14651858.CD001480.pub3.
29. Hotomi M., Billal D.S., Kamide Y., Kanesada K., Uno Y., Kudo F., et al. Serotype distribution and penicillin resistance of Streptococcus pneumoniae isolates from middle ear fluids of pediatric patients with acute otitis media in Japan. Clin Microbiol 2008, 46:3808-3810.
30. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360(3):244-256.
31. ® (pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)) [Package insert] 2010, Wyeth Pharmaceuticals, Inc., Philadelphia, USA.
32. Rozenbaum M.H., Boersma C., Postma M.J., Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines 2011, 10(February (2)):187-199.
33. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for economic evaluation of health care programmes 2004, Oxford University Press, Oxford. 3rd ed.
34. The Pharma Letter Pfizer gets US FDA approval for Prevnar 13, a Wyeth drug with blockbuster sales outlook 25 February 2010, The Pharma Letter, London, UK, http://www.thepharmaletter.com/file/52409/pfizer-gets-us-fda-approval-for-prevnar-13-a-wyeth-drug-with-blockbuster-sales-outlook.html [accessed 23.9.12].
35. Ishiwada N., Iwata S., Sakata H., Sakano T., Sato Y., Nakano T., et al. Burden of illness of pneumonia caused by Streptococcus pneumoniae in children. Jpn J Pediatr 2008, 61:2194-2204. [in Japanese].
36. Ministry of Health, Labour and Welfare Basic survey on wage structure 2009 2010, Health and Welfare Statistics Association, Tokyo, [in Japanese].
37. Ray G.T., Pelton S.I., Klugman K.P., Strutton D.R., Moore M.R. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine 2009, 27(47):6483-6494.
38. Shiroiwa T., Sung Y.K., Fukuda T., Lang H.C., Bae S.C., Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ 2010, 19(4):422-437.
39. World Health Organization WHO guide for standardization of economic evaluations of immunization programmes 2008, WHO Document Production Services, Geneva, Switzerland.
40. Sato T., Nakagomi T., Nakagomi O. Cost-effectiveness analysis of a universal rotavirus immunization program in Japan. Jpn J Infect Dis 2011, 64(4):277-283.
41. van Hoek A.J., Choi Y.H., Trotter C., Miller E., Jit M. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine 2012, 30(50):7205-7213.